AI
ACAD icon

Atria Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Atria Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$433K Sell
19,445
-2,557
-12% -$61.1K ﹤0.01% 1523
2025
Q4 		$588K Buy
22,002
+4,386
+25% +$105K 0.01% 1337
2025
Q3 		$376K Sell
17,616
-4,471
-20% -$106K ﹤0.01% 1593
2025
Q2 		$476K Buy
22,087
+4,574
+26% +$85K 0.01% 1450
2025
Q1 		$291K Buy
17,513
+4,111
+31% +$74.7K ﹤0.01% 1632
2024
Q4 		$246K Sell
13,402
-11,035
-45% -$178K ﹤0.01% 1694
2024
Q3 		$376K Buy
24,437
+2,384
+11% +$39.8K ﹤0.01% 1483
2024
Q2 		$358K Buy
+22,053
New +$356K ﹤0.01% 1482

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return